Arch Biopartners Inc.
ARCH.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -65.90K | -180.20K | 1.44M | 1.57M | 1.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.90K | -180.20K | 1.44M | 1.57M | 1.02M |
| Cost of Revenue | 531.90K | 794.70K | 2.74M | 2.79M | 1.14M |
| Gross Profit | -597.90K | -974.90K | -1.30M | -1.22M | -121.40K |
| SG&A Expenses | 822.10K | 853.10K | 917.30K | 1.32M | 1.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.35M | 1.65M | 3.66M | 4.12M | 2.43M |
| Operating Income | -1.42M | -1.83M | -2.22M | -2.54M | -1.41M |
| Income Before Tax | -1.72M | -2.19M | -2.61M | -2.88M | -1.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.72 | -2.19 | -2.61 | -2.88 | -1.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.72M | -2.19M | -2.61M | -2.88M | -1.89M |
| EBIT | -1.42M | -1.83M | -2.22M | -2.54M | -1.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.03 | -0.03 | -0.04 | -0.05 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.04 | -0.05 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 257.29M | 253.93M | 251.22M | 248.75M | 250.57M |
| Average Diluted Shares Outstanding | 257.29M | 253.93M | 251.22M | 248.75M | 250.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |